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Abstract
Background: Urine consists of a complex mixture of peptides and proteins and therefore is an
interesting source of biomarkers. Because of its high throughput capacity SELDI-TOF-MS is a
proteomics technology frequently used in biomarker studies. We compared the performance of
seven SELDI protein chip types for profiling of urine using standard chip protocols.
Results: Performance was assessed by determining the number of detectable peaks and spot to
spot variation for the seven array types and two different matrices: SPA and CHCA. A urine sample
taken from one healthy volunteer was applied in eight-fold for each chip type/matrix combination.
Data were analyzed for total number of detected peaks (S/N > 5). Spot to spot variation was
determined by calculating the average CV of peak intensities. In addition, an inventory was made of
detectable peaks with each chip and matrix type. Also the redundancy in peaks detected with the
different chip/matrix combinations was determined. A total of 425 peaks (136 non-redundant
peaks) could be detected when combining the data from the seven chip types and the two matrices.
Most peaks were detected with the CM10 chip with CHCA (57 peaks). The Q10 with CHCA (51
peaks), SEND (48 peaks) and CM10 with SPA (48 peaks) also performed well. The CM10 chip with
CHCA also has the best reproducibility with an average CV for peak intensity of 13%.
Conclusion: The combination of SEND, CM10 with CHCA, CM10 with SPA, IMAC-Cu with SPA
and H50 with CHCA provides the optimal information from the urine sample with good
reproducibility. With this combination a total of 217 peaks (71 non-redundant peaks) can be
detected with CV's ranging from 13 to 26%, depending on the chip and matrix type. Overall, CM10
with CHCA is the best performing chip type.
Background
Urine is an easily accessible body fluid which makes it an
interesting source of biomarkers for clinical and popula-
tion studies. Urine contains a complex mixture of proteins
and peptides and can be seen as the reflection of serum
composition and kidney function [1]. Protein content of
urine is relatively low compared to serum. Norden et al.
[2] estimated the excretion of proteins > 10 kDa on 33.7 ±
10.7 mg/24 hrs. Peptide excretion in the range of 750 Da
to 10 kDa was 22.0 ± 9.6 mg/24 hrs. Protein composition
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al. [3] and Davis et al. [4] could identify 124 proteins by
LC-MS/MS of a tryptic digest of urine. Oh et al. [5] could
annotate 113 different urinary proteins by 2D gel in com-
bination with depletion of high abundant proteins. Pieper
et al. [6] identified 150 unique proteins using a similar
approach. There is little overlap in the proteins identified
by the different methods employed [7]. Sun et al. [7]
could identify a total of 226 urinary proteins by combin-
ing results of different fractionation and mass spectrome-
try approaches. Although the proteomics methods
mentioned above have a high resolving power, they gen-
erally have a low throughput. For clinical or epidemiolog-
ical biomarker studies, where hundreds of samples are
compared, a high throughput proteomics technology is
essential. Because of its high throughput capacity, SELDI-
TOF-MS is often used in these types of studies. SELDI uses
proteinchip arrays with different affinity surfaces such as
hydrophobic chip types (SEND, H50 and H4), weak cat-
ion exchange (WCX, CM10), anion exchange (SAX2,
Q10), copper-coated IMAC chips and silica coated chips
(NP20). These can be used to reduce the sample complex-
ity which facilitates the detection of more proteins [8].
Several papers have been published thus far in which one
chip type or a combination of chip types were used for
SELDI profiling of urine. For example, Schaub et al. [9]
and Nguyen et al. [10] used NP20, Clarke et al used IMAC
and H4 chips [11], Zhang et al. used IMAC chips [12],
Dare et al. used SAX2 and H4 [13], Neuhoff et al. used
WCX chips [14], Traum et al. [15] and Khurana et al. [16]
used CM10 and IMAC chips and Voshol et al. used CM10
[17]. Woroniecki et al. [18] used a combination of CM10,
Q10 H50 and IMAC-30 chips. In these studies the differ-
ent chip types were processed either with SPA or CHCA as
matrix. In this manuscript we describe a study into the
performance of the different chip types for profiling of
urine using standard chip protocols. We investigated
intra-chip variability, the number of detected peaks and
the redundancy in detected peaks for the different array
types and two matrices (SPA and CHCA). The results facil-
itate the set-up of large scale SELDI-based biomarker stud-
ies with urine.
Results and discussion
For a comparison of SELDI chip performance with urine,
standard chip protocols as provided by Ciphergen were
applied. In these protocols the use of a bioprocessor is rec-
ommended for all chip types except SEND and NP20. The
bioprocessor is a 96-well format cassette that can maxi-
mally hold 12 chips and enables the incubation and
washing of the spots with larger volumes and facilitates
the incubation and washing steps. For NP20 and SEND
chips no standard bioprocessor protocols are provided.
Therefore, we evaluated the performance of these chip
types with a bioprocessor set-up. However, as shown in
Figure 1, they performed poorly with this set-up. As an
example, figure 1 (upper trace) shows a spectrum of non-
denatured urine obtained with a SEND chip and bioproc-
essor. When the same concentration of urine was applied
directly on the spot without making use of a bioprocessor,
the spectra improved considerable in terms of number of
detectable peaks (middle trace). Denaturation of urine
had a deteriorating effect on the spectra obtained with the
SEND chip (figure 1, lower trace). This was also observed
for the H4 chip (not shown). The reason for this is
unknown. However, the other chip types performed bet-
ter with denatured urine. Therefore, only SEND and H4
chips were processed using non-denatured urine. Details
of the protocols are provided in the methods section.
Protein profiles were generated by SELDI-TOF-MS. To test
intra-chip variability in terms of detected peaks the same
urine sample was applied to eight spots on one chip for
each chip type/matrix combination. SEND and CHCA
chips were measured in the mass range of 1 to 30 kDa (no
peaks could be detected above 30 kDa with this matrix
type) and SPA treated chips were measured in the mass
range of 1 to 100 kDa. Figure 2A shows examples of spec-
tra obtained in the 1 to 12 kDa mass range for CHCA.
Especially the H4, but also the Q10 spectra with CHCA,
suffer from considerable noise in the low mass region.
H50 and NP20 mainly show peaks below 3000 Da. Figure
2B depicts examples of spectra obtained with the different
chip types for the mass range of 10 to 100 kDa for SPA.
The SEND chip contains covalently bound CHCA that
reduces the chemical noise in the low mass region and
therefore cannot be used in combination with SPA as
matrix. The H50 chip performs poorly with SPA.
From the eight spectra obtained per chip and matrix type,
total number of peaks detected with a S/N>5 in one or
more of the eight spectra was determined (figure 3A). Best
chip types in terms of detectable peaks are CM10 with
CHCA (57 peaks), Q10 with CHCA (51 peaks), SEND (48
peaks) and CM10 with SPA (48 peaks). Another aspect of
chip performance is the reliability of the measurement.
Chip type/matrix combinations that yield spectra contain-
ing a relatively high number of peaks with high signal to
noise ratios will give more reliable results than combina-
tions that yield spectra with a relatively low number of
high signal to noise ratio peaks. To determine this we cal-
culated for each chip type/matrix combination the frac-
tion of the peaks that could be detected on all eight spots
with a S/N> 5. As shown in figure 3B, CM10 with CHCA
(54% in all eight spectra), SEND (50% in all eight spec-
tra), H50 with CHCA (50% in all eight spectra) and NP20
with CHCA (46% in all eight spectra) score best on this
aspect. In contrast, the Q10 chip, which has a relatively
high total peak number of 51 and 41 (figure 3A) for
CHCA and SPA, respectively, scores poorly on this featurePage 2 of 9
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This indicates that for urine the Q10 chip has a relative
large variation in signal to noise ratios between spots
compared to other chip types. The percentages of peaks
that have, in all replicates, signal to noise ratios higher
than a certain cut-off value (in this case S/N> 5) can there-
fore be considered as an indicator for chip performance.
The percentage value will depend on the chosen cut-off
signal to noise value. To determine intra-chip spot to spot
variation in peak intensities the average CV was calculated
for peaks with a S/N>5 in all eight spectra (figure 3C). The
CM10 chip with CHCA and the SEND chip performed the
best with average CV's of 13% and 15%, respectively.
Although Q10 with CHCA and NP20 with SPA also have
low CV's of 13% and 15%, respectively, these values were
based on only 4 and 3 peaks, respectively.
Besides peak count and reproducibility, also the distribu-
tion of the detected masses over the mass range was inves-
tigated as a parameter for chip performance. The
distribution of the detected peaks (S/N >5) over the 1–
100 kDa mass range was plotted for the different chip and
matrix types (figure 4). The evaluated mass range (1–100
kDa) was split into two ranges for a better visualization of
the masses distribution. For the low mass range (from 1 to
10 kDa), CM10 with CHCA (51 peaks) and SEND (43
peaks) show the most peaks (figure 4A). H50 with CHCA
(30 peaks) and NP20 (27 peaks) with CHCA are espe-
cially suitable in detecting peaks in the 1 to 2 kDa range.
For the high mass range (10 to 100 kDa, figure 4B), CM10
with SPA (20 peaks) and IMAC with SPA (17 peaks) show
the most peaks.
With the seven chip types and two matrix types, we were
able to detect 425 peaks (S/N > 5) in total. However, there
is considerable overlap in detected peaks between the dif-
ferent chip types. In Table 1 we estimated this redundancy
using a 0.3% mass variation, which is the standard value
Effect of the use of a bioprocessor and sample denaturation on the urinary protein profile obtained with a SEND chipFigure 1
Effect of the use of a bioprocessor and sample denaturation on the urinary protein profile obtained with a 
SEND chip. 200 μl of 2-fold diluted non-denatured urine in 0.1% TFA was incubated using the bioprocessor (upper trace); 2 
μl of non-denatured urine was directly applied to the spot without the use of a bioprocessor (middle trace); 2 μl of denatured 
urine directly applied to the spot without the use of a bioprocessor (lower trace). The same concentration was applied to all 
three conditions.Page 3 of 9
(page number not for citation purposes)
Proteome Science 2007, 5:2 http://www.proteomesci.com/content/5/1/2
Page 4 of 9
(page number not for citation purposes)
Urinary protein profiles obtained with the different chip typesFigure 2
Urinary protein profiles obtained with the different chip types. (A) Examples of urinary protein profiles for the 1 – 10 
kDa mass range obtained with the different chip types as indicated and CHCA as matrix. (B) Examples of urinary protein pro-
files for the 10 – 100 kDa mass range obtained with the different chip types as indicated and SPA as matrix.
Proteome Science 2007, 5:2 http://www.proteomesci.com/content/5/1/2used for cluster analyses of SELDI spectra. In total, 136
non-redundant peaks can be detected when combining all
chip types measured with CHCA as well as SPA, not taken
into account possible doubly charged ions. Most non-
redundant peaks were detected with the CM10 chip for
CHCA (20 peaks) as well as SPA (17 peaks) and the Q10
chip for CHCA (22 peaks) as well as SPA (14 peaks). The
H50 chip with CHCA also detects a considerable number
of non-redundant peaks (15 peaks). H4 with CHCA (0
peaks) and H4 with SPA (2 peaks), NP20 with SPA (3
peaks) and H50 with SPA (4 peaks) do not provide much
extra information which can not be obtained from other
chip and matrix combinations and therefore are of less
importance to use for profiling of urine.
Conclusion
Based on the results of this study, SEND, CM10 with
CHCA, CM10 with SPA, IMAC-Cu with SPA and H50 with
CHCA are the best performing combinations of chip and
matrix for protein profiling of urine with SELDI. When
urinary profiles generated from these chip/matrix types
are combined optimal information from a urine sample
with good reproducibility is obtained. A total of 217 peaks
(71 non-redundant peaks) can be detected with this com-
bination with CV's for peak intensity ranging from 13 to
26%, depending on the chip and matrix type (see figure
3B). This CV range for peak intensity is similar to that pre-
viously reported for SELDI analyses of serum and plasma
[19,20]. If the use of only one chip type is favored, the
CM10 chip is the best choice for urine profiling. Figure 3
indicates that with CHCA as well as with SPA this chip
type yields relatively high total peak numbers (57 and 48,
respectively) and low CV's for peak intensity (figure 3B).
Furthermore, a considerable number of peaks are only
detected with this chip type (see table 1). If profiling of
urine is intended in a particular mass range, several con-
siderations can be taken into account. The H50 chip with
CHCA is especially useful in the low mass range (below
2000 Da) while the IMAC-Cu chip with SPA is especially
useful in the 10 to 100 kDa mass range (figure 4). The
SEND chip performs best in the 2 to 7 kDa range but it is
not performing optimally with a bioprocessor set-up (fig-
ure 1). Therefore, this chip type can not be easily incorpo-
rated into an automated protocol using a pipetting robot,
as is normally the case in medium to large scale biomarker
studies. The chip protocols used in this study are general
and may need further refinement depending on specific
questions or interest in a certain mass range. The results of
this study may improve the outcome of SELDI based uri-
nary biomarker studies by facilitating choices for (combi-
nations of) chip and matrix types.
Assessment of chip performanceFigure 3
Assessment of chip performance. Overview of total 
peak number (panel A; S/N>5); percentage of peaks 
observed in all eight spectra with a S/N > 5 as a measure of 
reliability of the measurement (panel B) and the average CV 
(peak intensity) of those peaks detected in all eight spectra 
with a S/N>5 (panel C). Hatched bars represent CHCA, grey 
bars represent SPA and the black bar represents the SEND 
chip with covalently coupled CHCA. The different chip types 
used are indicated. Mass range for CHCA is 1–30 kDa, Mass 
range for SPA is 1–100 kDa.Page 5 of 9
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Distribution of the detected masses for the different chip typesFigure 4
Distribution of the detected masses for the different chip types. Distribution of the detected masses over the 1–10 
kDa (panel A) and 10–100 kDa mass range (panel B). Black dots represent masses detected with CHCA, black stripes repre-
sent masses detected with SPA and the crosses represent masses detected with the SEND chip with covalently coupled 
CHCA. The different chip types used are indicated.
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Sample pretreatment
Fresh human morning urine from a healthy male volun-
teer was centrifuged for 5 minutes at 7000 g and 4°C to
remove debris. The supernatant was used for further anal-
yses. Denatured urine was used for all chip types except
for SEND and H4. For denaturation, 160 μl of urine was
mixed with 60 μl of 9 M urea/2% CHAPS in 50 mM Tris
pH 9,0. The mixture was incubated at 4°C for 30 minutes
under continuous shaking.
Chip handling protocols
For the seven chip types tested, chip protocols used were
based on standard protocols provided by the chip manu-
facturer Ciphergen Biosystems. The sample was applied
manually to eight spots per condition (seven chip types
prepared with two matrix types, except for SEND which
has CHCA already incorporated as matrix). All chip types
were processed in a bioprocessor, except SEND and NP20.
The bioprocessor is a 96-well format cassette that can
maximally hold 12 chips and enables the incubation and
washing of the spots with larger volumes. The SEND chip
was activated by incubating the spots with 5 μl of 0.1%
TFA for 30 seconds without agitation. This was repeated
once. Then, 10 μl non-denatured urine was mixed with 10
μl 0.2% TFA and 2 μl of sample was applied per spot. The
array was incubated for 10 minutes in a humidity cham-
ber (closed box with wet tissue) at room temperature.
Thereafter, the samples were removed and spots were
washed with 5 μl of 0.1% TFA for 30 seconds. Then, 2 μl
of 25% ACN (v/v) and 0.1% TFA in water was added and
spots were allowed to air-dry. No matrix addition is nec-
essary since the SEND chip surface contains covalently
linked CHCA.
Spots on a NP20 chip were incubated for 20 minutes with
5 μl of denatured urine in a humidity chamber. Thereaf-
ter, spots were washed three times with 5 μl of ultra pure
water and were air-dried. Then, two times 0.5 μl of matrix
solution was applied. A saturated solution of SPA and a 5-
fold diluted saturated solution of CHCA in 50% ACN (v/
v), 0.5% TFA (v/v) were used.
For the other chip types a bioprocessor was used for incu-
bation and washing steps. As a first step before addition of
binding buffer, some chip types (H50, H4 and IMAC30)
require activation as detailed below. The spots of the H50
chip were activated by washing twice with 5 μl 50 % ACN/
water for 5 minutes. The chip was then air-dried for 15
minutes. Spots on the H4 array were pre-treated with 5 μl
ACN and air-dried. The spots on the IMAC30 chip were
loaded with 50 μl of 100 mM CuSO4 and incubated for 5
minutes. Thereafter, they were washed twice for 5 minutes
with 200 μl ultra pure water, once with 50 μl of 100 mM
NH4Ac pH 4.0 and once with 200 μl water. Next, for all
chip types, 200 μl binding buffer was added to the wells.
The buffer composition depends on the chip type. This
was: for CM10, 100 mM NH4Ac pH 4.0 + 0.05% Triton;
for Q10, 100 mM Tris HCl pH 10 + 0.05 % Triton; for
IMAC, 0.5 M NaCl in PBS pH 7.4 + 0.1 % Triton; for H50,
10 % ACN, 0.1% TFA in PBS pH 7.4; for H4 10 % ACN,
0.25 M NaCl in PBS pH 7.4. The spots were incubated for
5 minutes at room temperature with agitation (250 rpm).
This was repeated once. The buffer was removed and
replaced by 160 μl binding buffer and 40 μl of urine
(denatured, except for H4) and incubated for 30 minutes.
After incubation, the sample was removed and spots were
washed three times for 5 minutes with 200 μl binding
buffer and once with 200 μl ultra pure water. After
Table 1: Peak number and redundancy per chip and matrix type.
SEND CM10 H50 H4 IMAC30 NP20 Q10
CHCA SPA CHCA SPA CHCA SPA CHCA SPA CHCA SPA CHCA SPA Total
Nr of peaks 48 57 48 36 12 5 15 35 28 37 12 51 41 425
SEND 15 11 1 0 1 3 14 6 5 2 10 4
CM10 CHCA 15 10 6 0 0 2 15 5 10 1 5 4
SPA 11 10 1 2 1 7 8 14 4 3 1 7
H50 CHCA 1 6 1 1 0 2 2 2 14 1 0 0
SPA 0 0 2 1 1 2 1 2 0 4 1 4
H4 CHCA 1 0 1 0 1 1 0 0 0 1 2 2
SPA 3 2 7 2 2 1 4 3 1 4 2 3
IMAC30 CHCA 14 15 8 2 1 0 4 4 6 3 8 2
SPA 6 5 14 2 2 0 3 4 3 2 2 4
NP20 CHCA 5 10 4 14 0 0 1 6 3 2 2 0
SPA 2 1 3 1 4 1 4 3 2 2 2 1
Q10 CHCA 10 5 1 0 1 2 2 8 2 2 2 7
SPA 4 4 7 0 4 2 3 2 4 0 1 7
Non-redundant peaks 11 20 17 15 4 0 2 9 8 11 3 22 14 136
a) Peak number was determined using a threshold of S/N >5. Redundancy was calculated using a 0.3% mass variation. Mass range for CHCA is 1–30 
kDa, Mass range for SPA is 1–100 kDa.Page 7 of 9
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applying two times 0.5 μl of matrix solution, prepared as
described above.
Data acquisition and processing
Protein profiles were generated in a SELDI-TOF-MS
(Ciphergen Biosystems). SEND and CHCA chips were
measured in the mass range of 1 to 30 kDa. SPA treated
chips were measured in the mass range of 1 to 100 kDa.
91 transients were averaged in the final spectra. Source
voltage was 20000 V, detector voltage was 2050 V. Cali-
bration was performed with the All-in-One peptide mix
(Ciphergen Biosystems).
Proteinchip software 3.1 with the integrated Biomarker
Wizard™ cluster analyses software (Ciphergen Biosys-
tems) [21] was used for data analysis. The baseline was
subtracted and profiles were normalized using total ion
current before further analyses. Using the cluster analyses
tool, peaks (clusters) with signal to noise ratios (S/N)
higher than 5 were selected from the eight spectra. This
yields the total number of peaks present in one or more of
the eight spectra. For each cluster, it is listed in how many
spectra a peak is detected with a S/N>5. In this way, the
fraction of peaks that is detectable in all 8 spectra with a
S/N>5 was calculated as an indicator of the number of
high signal to noise peaks detected with a certain chip
type/matrix combination. As a measure of spot to spot
variation the average coefficient of variation (CV) of peak
intensities was calculated for those peaks that were
detected in all 8 spectra with a S/N>5.
Abbreviations
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